22157.jpg
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
April 26, 2024 04:12 ET | Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "NK Cell Therapies - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Global Natural Killer Cells Therapeutics Market
Global Natural Killer Cells Therapeutics Research Report 2023: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2022 and 2023-2028
January 03, 2024 11:33 ET | Research and Markets
Dublin, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The "Global Natural Killer Cells Therapeutics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
22157.jpg
Anti-CD38 Antibody Pipeline Research Report 2023 Featuring Sorrento Therapeutics, I-MAB Biopharma, Takeda, Hangzhou Sumgen Biotech, Wuhan YZY Biopharma, and Biomunex Pharmaceuticals
November 22, 2023 08:38 ET | Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Anti-CD38 antibody - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
22157.jpg
Natural Killer Cells Therapeutics Market Analysis and Industry Forecast to 2027: Advancements in Manufacturing Processes, Cell Engineering Techniques and Development of Combination Therapies
August 07, 2023 06:03 ET | Research and Markets
Dublin, Aug. 07, 2023 (GLOBE NEWSWIRE) -- The "Natural Killer Cells Therapeutics Market by Therapeutics, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2027" report...
22157.jpg
Elotuzumab Emerging Drug Insight and Market Forecast 2022-2032: Comprehensive Analysis on Drug Mechanisms, R&D Activities, Key Players and Emerging Therapies
February 16, 2023 11:13 ET | Research and Markets
Dublin, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The "Elotuzumab Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides...
22157.jpg
Natural Killer Cells Therapeutics Global Market Report 2022: Rise in Awareness about Immunotherapies Bolsters Sector
December 09, 2022 05:33 ET | Research and Markets
Dublin, Dec. 09, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer Cells Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Natural Killer...
22157.jpg
2022 Outlook on the Anti TIGIT Antibody Global Market: By Phase, Company, Country and Indication
December 05, 2022 06:33 ET | Research and Markets
Dublin, Dec. 05, 2022 (GLOBE NEWSWIRE) -- The "Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023" report has been added to ResearchAndMarkets.com's offering. This report...
Global Natural Killer (NK) Cell Therapeutics Market
Natural Killer (NK) Cell Therapeutics Market Research Report 2022
August 09, 2022 06:08 ET | Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer (NK) Cell Therapeutics Market - A Global and Regional Analysis: Focus on NK Cell Therapy Type, Indication, Country, Pipeline Analysis,...
Global Natural Killer Cells Therapeutics Market
Insights on the Natural Killer Cells Therapeutics Global Market to 2027 - by Therapeutics, Application, End-user and Region
July 01, 2022 07:13 ET | Research and Markets
Dublin, July 01, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Global Cellular Immunotherapy Market
Global Cellular Immunotherapy Market (2022 to 2031) - Featuring Novartis, Gilead Sciences and Dendreon Pharmaceuticals Among Others
March 22, 2022 05:18 ET | Research and Markets
Dublin, March 22, 2022 (GLOBE NEWSWIRE) -- The "Cellular Immunotherapy Global Market Report 2022: By Therapy, By Primary, By Application" report has been added to ResearchAndMarkets.com's offering....